Results 91 to 100 of about 48,562 (198)
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Psoriasis: Targets and Therapy, 2019 Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence ...
Ly K +4 more
doaj
Janus kinase inhibitors in the treatment of inflammatory rheumatic diseases [PDF]
, 2019 Paradigma liječenja upalnih reumatskih bolesti značajno se mijenjala kroz povijest novim spoznajama o patogenezi i otkrićima bazičnih medicinskih znanosti općenito.
Čaić, Mislav
core
SAGE Open Medical Case ReportsThis case report describes, to our knowledge, the first known successful treatment of airborne allergic contact dermatitis to sesquiterpene lactone with upadacitinib in an adult patient.
Barbara Marzario +2 more
doaj +1 more source
Advancing therapeutic frontiers: a pipeline of novel drugs for UC management
Frontiers in GastroenterologyUlcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors
Luisa Bertin +9 more
doaj +1 more source
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
, 2014 Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.
Levine, Ross L, Meyer, Sara C
core +1 more source
Funktionelle Charakterisierung von Mitgliedern des MicroRNA-17-92-Clusters im Blutgefäßsystem
, 2011 Almost two decades ago, microRNAs were discovered as novel posttranscriptional regulators of gene expression. Since then, research efforts have uncovered their involvement in the control of various cellular processes including migration, proliferation ...
Döbele, Carmen
core
Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors
, 2016 Developing Janus kinase 2 (Jak2) inhibitors has become a significant focus for small molecule drug discovery programs in recent years due to the identification of a Jak2 gain-of-function mutation in the majority of patients with myeloproliferative ...
Elizabeth Doherty (2134036) +21 more
core +1 more source
Public Interest in Janus Kinase (JAK) Inhibitors for Alopecia Areata: A Google Trend Analysis
JMIR DermatologyPublic interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on ...
Jade Howard +3 more
doaj +1 more source
Objective This systematic literature review (SLR) on efficacy outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with Janus kinase inhibitors (JAKi ...
Nash, P +31 more
core +1 more source